MTOR and autosomal dominant polycystic kidney disease: Similarly, while the mechanisms that account for elevated mTOR activity in ADPKD are not fully understood, very convincing pre-clinical data from animal studies demonstrating that mTOR inhibition ameliorates cystic disease served as the basis for human trials of this approach (11–21).